NovoCure Ltd. (NASDAQ:NVCR) shares rose 3.7% on Friday . The stock traded as high as $8.09 and last traded at $8.04, with a volume of 149,998 shares traded. The stock had previously closed at $7.75.

NVCR has been the topic of several research analyst reports. Zacks Investment Research cut shares of NovoCure from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. JPMorgan Chase & Co. reduced their price target on shares of NovoCure from $29.00 to $14.00 and set an “overweight” rating on the stock in a research report on Friday, July 29th. Wedbush reiterated an “outperform” rating and set a $30.00 price target on shares of NovoCure in a research report on Wednesday, July 6th. Deutsche Bank AG reduced their price target on shares of NovoCure from $28.00 to $16.00 and set a “hold” rating on the stock in a research report on Friday, July 29th. Finally, Barclays PLC reduced their price target on shares of NovoCure from $12.00 to $9.00 and set an “underweight” rating on the stock in a research report on Friday, July 29th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $21.43.

The firm’s 50 day moving average price is $8.80 and its 200-day moving average price is $11.68. The company’s market capitalization is $690.48 million.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings data on Thursday, July 28th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.11. The firm earned $17.90 million during the quarter, compared to analysts’ expectations of $15.90 million. On average, equities research analysts forecast that NovoCure Ltd. will post ($1.74) EPS for the current year.

In other news, COO Michael J. Ambrogi sold 20,000 shares of NovoCure stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $12.24, for a total transaction of $244,800.00. Following the transaction, the chief operating officer now directly owns 324,084 shares of the company’s stock, valued at approximately $3,966,788.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gert L. Perlhagen sold 676,576 shares of the business’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $1.85, for a total value of $1,251,665.60. Following the completion of the transaction, the director now directly owns 676,576 shares in the company, valued at $1,251,665.60. The disclosure for this sale can be found here.

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.